Page last updated: 2024-08-25

s20098 and mdl 100907

s20098 has been researched along with mdl 100907 in 54 studies

Research

Studies (54)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	25 (46.30)	29.6817
2010's	29 (53.70)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chagraoui, A; Filloux, T; Mocaër, E; Protais, P	1
Fuchs, E; Schmelting, B; Simon, M	1
Bertaina-Anglade, V; Boyer, PA; la Rochelle, CD; Mocaër, E	1
Guilleminault, C; Zupancic, M	1
Kasper, S; Konstantinidis, A; Pjrek, E; Praschak-Rieder, N; Willeit, M; Winkler, D	1
Bánki, MC	1
Kasper, S; Olié, JP	1
Baghai, TC; Eser, D; Möller, HJ	1
Lam, RW	2
Popoli, M; Racagni, G; Riva, MA	1
Arranz, B; San, L	1
Cardinali, DP; Hardeland, R; Pandi-Perumal, SR; Poeggeler, B; Spence, DW; Srinivasan, V; Trakht, I	1
Goodwin, GM	2
Gorwood, P; Le Strat, Y	1
Kennedy, SH	2
Ahokas, AA; de Bodinat, C; Stein, DJ	1
Hamon, M; Kasper, S	1
Bourin, M; Prica, C	1
Banasr, M; Bernard, N; Daszuta, A; Gabriel, C; Kerkerian-Le-Goff, L; Lortet, S; Masmejean, F; Millan, MJ; Mocaer, E; Soumier, A	1
Emsley, R; Goodwin, GM; Rembry, S; Rouillon, F	1
Popoli, M	1
Dubovsky, SL; Warren, C	1
Kennedy, SH; Rizvi, SJ	1
Baldwin, DS; Bazire, S; Haddad, PM; McAllister-Williams, RH	1
de Bodinat, C; Guardiola-Lemaitre, B; Millan, MJ; Mocaër, E; Muñoz, C; Renard, P	1
Corral, RM; Gentil, V; Hale, A; Mencacci, C; Ruiz, JS; Severo, CA	1
Bockaert, J; Chanrion, B; Jockers, R; Kamal, M; Labasque, M; Mannoury la Cour, C; Marin, P; Millan, MJ	1
Bertaina-Anglade, V; Drieu-La-Rochelle, C; Mocaër, E; Seguin, L	1
David, DJ; Enhamre, E; Gabriel, C; Gardier, AM; Guilloux, JP; Hen, R; Mocaër, E; Rainer, Q; Xia, L	1
Alvarez, JC; Barbot, F; Guilleminault, C; Hartley, S; Lofaso, F; Quera Salva, MA	1
Calabrese, F; Molteni, R; Musazzi, L; Popoli, M; Racagni, G; Riva, MA; Tardito, D	1
Gromova, SA; Sergeev, AV; Tabeeva, GR	1
Cranston, I; Dekeyne, A; Gabriel, C; Irons, JA; Millan, MJ; Mocaër, E; Norman, TR	1
Hopkins, CR	1
De Berardis, D; Di Giannantonio, M; Marini, S; Martinotti, G; Moschetta, FS; Serroni, N	1
Smirnova, VN; Tiuvina, NA	1
Bhutada, P; Deshmukh, P; Dixit, P; Kaulaskar, S; Thakur, K	1
Hajak, G; Kasper, S	1
Corbach-Söhle, S; Flügge, G; Fuchs, E; Kohlhause, S; Schlumbohm, C; Schmelting, B	1
Berthelot, P; Boutin, JA; Caignard, DH; Delagrange, P; Ettaoussi, M; Landagaray, E; Nosjean, O; Pérès, B; Sabaouni, A; Yous, S	1
Delmonte, D; Smeraldi, E	1
Carvalho, AF; Cha, DS; MacIsaac, SE; Mansur, RB; McIntyre, RS	1
Avedisova, A; Belaïdi, C; de Bodinat, C; Giménez-Montesinos, N; Kennedy, SH	1
Amore, M; Benassi, F; Cocito, L; Cordano, C; Emberti Gialloreti, L; Guida, S; Mattei, C; Pardini, M; Primavera, A; Sassos, D; Serrati, C	1
De Bodinat, C; Delagrange, P; Guardiola-Lemaitre, B; Millan, MJ; Mocaër, E; Munoz, C	1
Boulle, F; Gabriel, C; Lanfumey, L; Marday, S; Massart, R; Mocaer, E; Mongeau, R; Païzanis, E; Stragier, E; Zaidan, L	1
Noori, HR; Spanagel, R; Vengeliene, V	1
Bogdanovskaya, M; Cowen, PJ; Harmer, CJ; Pringle, A; Waskett, P; Zacharia, S	1
Egorov, AY	1
Amore, M; Benassi, F; Callegari, I; Cocito, L; Emberti Gialloreti, L; Grafman, J; Krueger, F; Massucco, D; Mattei, C; Nobili, F; Pardini, M; Sassos, D; Scialò, C; Serrati, C; Yaldizli, Ö	1
Hagino, Y; Ide, S; Ikeda, K; Kamegaya, E; Matsuzawa, M; Mishina, M; Sawada, W; Takamatsu, Y; Yamamoto, H; Yamamoto, T	1

Reviews

25 review(s) available for s20098 and mdl 100907

Article	Year
Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system. International clinical psychopharmacology, 2006, Volume: 21 Suppl 1 Topics: Acetamides; Animals; Antidepressive Agents; Biological Clocks; Brain; Depressive Disorder, Major; Disease Models, Animal; Drug Evaluation, Preclinical; Drugs, Investigational; Humans; Melatonin; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Antagonists; Tupaiidae	2006
Agomelatine: a preliminary review of a new antidepressant. CNS drugs, 2006, Volume: 20, Issue:12 Topics: Acetamides; Animals; Antidepressive Agents; Depressive Disorder, Major; Humans; Hypnotics and Sedatives; Receptors, Melatonin; Serotonin 5-HT2 Receptor Antagonists	2006
[Agomelatine: the first "melatoninergic" antidepressant]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, 2006, Volume: 8, Issue:3 Topics: Acetamides; Animals; Anti-Anxiety Agents; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Disease Models, Animal; Humans; Hypnotics and Sedatives; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists; Sleep	2006
Evidence of agomelatine's antidepressant efficacy: the key points. International clinical psychopharmacology, 2007, Volume: 22 Suppl 2 Topics: Acetamides; Anti-Anxiety Agents; Antidepressive Agents; Circadian Rhythm; Depressive Disorder; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists	2007
High-quality remission: potential benefits of the melatonergic approach for patients with major depressive disorder. International clinical psychopharmacology, 2007, Volume: 22 Suppl 2 Topics: Acetamides; Antidepressive Agents; Depressive Disorder, Major; Humans; Hypnotics and Sedatives; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists	2007
The interaction between the internal clock and antidepressant efficacy. International clinical psychopharmacology, 2007, Volume: 22 Suppl 2 Topics: Acetamides; Animals; Antidepressive Agents; Biological Clocks; Circadian Rhythm; Depressive Disorder; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Antagonists; Suprachiasmatic Nucleus	2007
Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. European psychiatry : the journal of the Association of European Psychiatrists, 2008, Volume: 23, Issue:6 Topics: Acetamides; Animals; Circadian Rhythm; Depressive Disorder, Major; Dopamine; Frontal Lobe; Humans; Hypnotics and Sedatives; Melatonin; Norepinephrine; Randomized Controlled Trials as Topic; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists	2008
The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2009, Volume: 10, Issue:4 Pt 2 Topics: Acetamides; Affect; Antidepressive Agents; Brain; Depressive Disorder, Major; Humans; Indenes; Melatonin; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Sleep; Sleep Initiation and Maintenance Disorders	2009
Agomelatine, an innovative pharmacological response to unmet needs. Journal of psychopharmacology (Oxford, England), 2008, Volume: 22, Issue:7 Suppl Topics: Acetamides; Animals; Antidepressive Agents; Chronic Disease; Circadian Rhythm; Depressive Disorder, Major; Humans; Models, Animal; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Treatment Outcome	2008
Innovation translates into antidepressant effectiveness. Journal of psychopharmacology (Oxford, England), 2008, Volume: 22, Issue:7 Suppl Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; Depressive Disorder; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Severity of Illness Index; Time Factors; Treatment Outcome	2008
Addressing circadian rhythm disturbances in depressed patients. Journal of psychopharmacology (Oxford, England), 2008, Volume: 22, Issue:7 Suppl Topics: Acetamides; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Sleep; Sleep Disorders, Circadian Rhythm; Time Factors; Treatment Outcome	2008
Treating each and every depressed patient. Journal of psychopharmacology (Oxford, England), 2008, Volume: 22, Issue:7 Suppl Topics: Acetamides; Age Factors; Antidepressive Agents; Anxiety; Chronic Disease; Circadian Rhythm; Depressive Disorder, Major; Female; Humans; Male; Patient Selection; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Severity of Illness Index; Sex Factors; Sleep; Time Factors; Treatment Outcome	2008
Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2009, Volume: 10, Issue:2 Topics: Acetamides; Animals; Anti-Anxiety Agents; Antidepressive Agents; Circadian Rhythm; Depressive Disorder; Depressive Disorder, Major; Dopamine; Humans; Hypnotics and Sedatives; Norepinephrine; Randomized Controlled Trials as Topic; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin; Serotonin 5-HT2 Receptor Antagonists	2009
Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression. Current pharmaceutical design, 2009, Volume: 15, Issue:14 Topics: Acetamides; Animals; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder; Drug Delivery Systems; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists; Severity of Illness Index	2009
Agomelatine: innovative pharmacological approach in depression. CNS drugs, 2009, Volume: 23 Suppl 2 Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Disease Models, Animal; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists; Sleep Wake Disorders	2009
Agomelatine: efficacy at each phase of antidepressant treatment. CNS drugs, 2009, Volume: 23 Suppl 2 Topics: Acetamides; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Psychiatric Status Rating Scales; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists; Sleep Wake Disorders	2009
Agomelatine, a melatonin agonist with antidepressant properties. Expert opinion on investigational drugs, 2009, Volume: 18, Issue:10 Topics: Acetamides; Animals; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists; Sleep	2009
Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS drugs, 2010, Volume: 24, Issue:6 Topics: Acetamides; Antidepressive Agents; Anxiety Disorders; Depressive Disorder, Major; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists	2010
The use of antidepressants in clinical practice: focus on agomelatine. Human psychopharmacology, 2010, Volume: 25, Issue:2 Topics: Acetamides; Animals; Antidepressive Agents; Contraindications; Depressive Disorder, Major; Drug Interactions; Drug Monitoring; Fluvoxamine; Humans; Liver; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists; Substance Withdrawal Syndrome	2010
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nature reviews. Drug discovery, 2010, Volume: 9, Issue:8 Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Drug Design; Drug Discovery; Humans; Melatonin; Serotonin 5-HT2 Receptor Antagonists	2010
Circadian rhythms, melatonin and depression. Current pharmaceutical design, 2011, Volume: 17, Issue:15 Topics: Acetamides; Animals; Antidepressive Agents; Biological Clocks; Chronobiology Disorders; Depressive Disorder, Major; Humans; Melatonin; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists	2011
Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2011, Volume: 12, Issue:8 Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; Depression; Humans; Receptor, Serotonin, 5-HT2C; Receptors, Melatonin; Serotonin 5-HT2 Receptor Antagonists	2011
Agomelatine in depression. Expert opinion on drug safety, 2013, Volume: 12, Issue:6 Topics: Acetamides; Animals; Antidepressive Agents; Bipolar Disorder; Depressive Disorder, Major; Humans; Melatonin; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome	2013
The mechanism, efficacy, and tolerability profile of agomelatine. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:2 Topics: Acetamides; Animals; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Disease Models, Animal; Humans; Neurogenesis; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists	2014
Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties. British journal of pharmacology, 2014, Volume: 171, Issue:15 Topics: Acetamides; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Circadian Rhythm; Depression; Humans; Neurogenesis; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists	2014

Trials

10 trial(s) available for s20098 and mdl 100907

Article	Year
Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology, 2007, Volume: 190, Issue:4 Topics: Acetamides; Adult; Antidepressive Agents; Circadian Rhythm; Female; Humans; Male; Middle Aged; Pilot Projects; Psychiatric Status Rating Scales; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Seasonal Affective Disorder; Serotonin 5-HT2 Receptor Antagonists; Sleep; Time Factors; Treatment Outcome	2007
Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. The international journal of neuropsychopharmacology, 2007, Volume: 10, Issue:5 Topics: Acetamides; Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Prospective Studies; Receptors, Melatonin; Serotonin 5-HT2 Receptor Antagonists; Severity of Illness Index; Time Factors; Treatment Outcome	2007
Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:5 Topics: Acetamides; Adolescent; Adult; Aged; Anxiety Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Psychiatric Status Rating Scales; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome	2008
Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. The Journal of clinical psychiatry, 2009, Volume: 70, Issue:8 Topics: Acetamides; Adolescent; Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypnotics and Sedatives; Kaplan-Meier Estimate; Male; Melatonin; Middle Aged; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Secondary Prevention; Serotonin 5-HT2 Receptor Antagonists; Substance Withdrawal Syndrome; Treatment Outcome	2009
Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. International clinical psychopharmacology, 2010, Volume: 25, Issue:6 Topics: Acetamides; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Fluoxetine; Humans; Internationality; Male; Middle Aged; Patient Dropouts; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Severity of Illness Index; Young Adult	2010
[Possibilities of preventive treatment of migraine with the MT1- and MT2 agonist and 5-HT2с receptor antagonist agomelatin (valdoxan)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2011, Volume: 111, Issue:9 Topics: Acetamides; Adult; Female; Humans; Male; Middle Aged; Migraine Disorders; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome; Young Adult	2011
The efficacy of agomelatine in previously-treated depressed patients. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2013, Volume: 23, Issue:8 Topics: Acetamides; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Monitoring; Drug Resistance; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Psychiatric Status Rating Scales; Receptors, Melatonin; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Sertraline	2013
A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2014, Volume: 24, Issue:4 Topics: Acetamides; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug Monitoring; Female; Humans; Male; Middle Aged; Patient Dropouts; Psychiatric Status Rating Scales; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Antagonists; Severity of Illness Index; Young Adult	2014
Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2014, Volume: 24, Issue:6 Topics: Acetamides; Adult; Antidepressive Agents; Fatigue; Fatigue Syndrome, Chronic; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Melatonin; Pilot Projects; Psychiatric Status Rating Scales; Quality of Life; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome	2014
[The use of agomelatine (valdoxan) in gambling therapy: a pilot study]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015, Volume: 115, Issue:9 Topics: Acetamides; Adult; Antidepressive Agents; Anxiety; Female; Gambling; Humans; International Classification of Diseases; Male; Middle Aged; Pilot Projects; Psychiatric Status Rating Scales; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome; Young Adult	2015

Other Studies

19 other study(ies) available for s20098 and mdl 100907

Article	Year
Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats. Psychopharmacology, 2003, Volume: 170, Issue:1 Topics: Acetamides; Animals; Antidepressive Agents; Choroid Plexus; In Vitro Techniques; Indoles; Inositol Phosphates; Male; Melatonin; Naphthalenes; Penile Erection; Pizotyline; Pyridines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2C; Receptors, Melatonin; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Swine	2003
Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behavioural pharmacology, 2006, Volume: 17, Issue:8 Topics: Acetamides; Aminopyridines; Animals; Antidepressive Agents; Avoidance Learning; Helplessness, Learned; Imipramine; Indoles; Male; Melatonin; Rats; Rats, Wistar; Receptors, Melatonin; Serotonin 5-HT2 Receptor Antagonists; Thiophenes	2006
Major depression is sometimes described as the common cold of psychiatry. Journal of psychopharmacology (Oxford, England), 2008, Volume: 22, Issue:7 Suppl Topics: Acetamides; Animals; Antidepressive Agents; Chronic Disease; Circadian Rhythm; Depressive Disorder, Major; Humans; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Treatment Outcome	2008
Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2009, Volume: 34, Issue:11 Topics: Acetamides; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cell Proliferation; Cell Survival; Hippocampus; Insulin-Like Growth Factor I; Male; Neurogenesis; Neurons; Rats; Rats, Wistar; Receptors, Melatonin; Serotonin 5-HT2 Receptor Antagonists; Signal Transduction; Vascular Endothelial Growth Factor A	2009
The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT(2C) receptors. The international journal of neuropsychopharmacology, 2011, Volume: 14, Issue:6 Topics: Acetamides; Animals; Antidepressive Agents; Arrestins; beta-Arrestins; Calcium Signaling; Cell Membrane; Cells, Cultured; GTP-Binding Protein alpha Subunits; GTP-Binding Protein alpha Subunits, Gq-G11; Guanosine 5'-O-(3-Thiotriphosphate); HEK293 Cells; Humans; Kinetics; Ligands; Mice; Neurons; Receptor, Serotonin, 5-HT2C; Receptors, Melatonin; Recombinant Fusion Proteins; Recombinant Proteins; Serotonin; Serotonin 5-HT2 Receptor Antagonists	2011
Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat. Pharmacology, biochemistry, and behavior, 2011, Volume: 98, Issue:4 Topics: Acetamides; Aminopyridines; Animals; Antidepressive Agents; Drug Chronotherapy; Indoles; Male; Melatonin; Memory; Rats; Rats, Sprague-Dawley; Recognition, Psychology; Serotonin; Serotonin 5-HT2 Receptor Antagonists	2011
Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety. The international journal of neuropsychopharmacology, 2012, Volume: 15, Issue:3 Topics: Acetamides; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Cell Proliferation; Circadian Rhythm; Corticosterone; Dendrites; Depressive Disorder; Disease Models, Animal; Fluoxetine; Hippocampus; Male; Mice, Inbred C57BL; Motor Activity; Neurogenesis; Neurons; Serotonin 5-HT2 Receptor Antagonists	2012
Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: a comparison to melatonin and to the 5-HT(2c) antagonist, S32006. European journal of pharmacology, 2012, Jan-05, Volume: 674, Issue:1 Topics: Acetamides; Animals; Antidepressive Agents; Behavior, Animal; Hyperkinesis; Indoles; Male; Melatonin; Olfactory Bulb; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Antagonists	2012
ACS chemical neuroscience molecule spotlight on Valdoxen. ACS chemical neuroscience, 2010, Dec-15, Volume: 1, Issue:12 Topics: Acetamides; Animals; Antidepressive Agents; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Evaluation, Preclinical; Fatigue; Headache; Humans; Nausea; Norepinephrine; Randomized Controlled Trials as Topic; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Antagonists	2010
Agomelatine for the treatment of posttraumatic stress disorder: a case report. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2012, Volume: 24, Issue:3 Topics: Acetamides; Adult; Female; Humans; Hypnotics and Sedatives; Receptors, Melatonin; Serotonin 5-HT2 Receptor Antagonists; Stress Disorders, Post-Traumatic	2012
[A comparative evaluation of the efficacy of valdoxan (agomelatine) in recurrent depression and bipolar affective disorder]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2012, Volume: 112, Issue:11 Pt 2 Topics: Acetamides; Adult; Antidepressive Agents; Bipolar Disorder; Circadian Rhythm; Depressive Disorder; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Psychometrics; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome	2012
Effects of agomelatine in a murine model of obsessive-compulsive disorder: interaction with meta-chlorophenylpiperazine, bicuculline, and diazepam. The Kaohsiung journal of medical sciences, 2013, Volume: 29, Issue:7 Topics: Acetamides; Animals; Antidepressive Agents; Behavior, Animal; Bicuculline; Diazepam; Disease Models, Animal; Drug Interactions; GABA-A Receptor Agonists; GABA-A Receptor Antagonists; Male; Mice; Mice, Inbred C57BL; Motor Activity; Obsessive-Compulsive Disorder; Piperazines; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists	2013
Agomelatine in the tree shrew model of depression: effects on stress-induced nocturnal hyperthermia and hormonal status. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2014, Volume: 24, Issue:3 Topics: Acetamides; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Body Temperature; Body Weight; Central Nervous System Depressants; Circadian Rhythm; Depressive Disorder; Fever; Fluoxetine; Hydrocortisone; Indoles; Male; Melatonin; Motor Activity; Norepinephrine; Pyridines; Serotonin 5-HT2 Receptor Antagonists; Stress, Psychological; Tupaiidae	2014
Synthesis and pharmacological evaluation of a series of the agomelatine analogues as melatonin MT1 /MT2 agonist and 5-HT2C antagonist. ChemMedChem, 2013, Volume: 8, Issue:11 Topics: Acetamides; Animals; CHO Cells; Cricetulus; Humans; Hypnotics and Sedatives; Molecular Structure; Naphthalenes; Protein Binding; Receptor, Melatonin, MT1; Serotonin 5-HT2 Receptor Antagonists	2013
Hippocampal and behavioral dysfunctions in a mouse model of environmental stress: normalization by agomelatine. Translational psychiatry, 2014, Nov-25, Volume: 4 Topics: Acetamides; Affective Symptoms; Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Epigenesis, Genetic; Hippocampus; Male; Mice; Mice, Inbred C57BL; Neuronal Plasticity; Psychomotor Agitation; Receptors, Melatonin; Serotonin 5-HT2 Receptor Antagonists; Signal Transduction; Stress, Psychological	2014
Activation of Melatonin Receptors Reduces Relapse-Like Alcohol Consumption. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015, Volume: 40, Issue:13 Topics: Acetamides; Alcohol Deterrents; Alcohol Drinking; Alcohol-Related Disorders; Aminopyridines; Animals; Choice Behavior; Circadian Rhythm; Disease Models, Animal; Indoles; Male; Melatonin; Motor Activity; Rats, Wistar; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Recurrence; Serotonin 5-HT2 Receptor Antagonists	2015
Does melatonin treatment change emotional processing? Implications for understanding the antidepressant mechanism of agomelatine. Journal of psychopharmacology (Oxford, England), 2015, Volume: 29, Issue:10 Topics: Acetamides; Adolescent; Adult; Antidepressive Agents; Circadian Rhythm; Double-Blind Method; Emotions; Female; Healthy Volunteers; Humans; Male; Melatonin; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Antagonists; Young Adult	2015
Agomelatine Improves Apathy in Frontotemporal Dementia. Neuro-degenerative diseases, 2016, Volume: 16, Issue:5-6 Topics: Acetamides; Antidepressive Agents; Apathy; Double-Blind Method; Female; Frontotemporal Dementia; Humans; Male; Melatonin; Middle Aged; Psychiatric Status Rating Scales; Receptor, Melatonin, MT1; Receptor, Melatonin, MT2; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome	2016
Loss of GluN2D subunit results in social recognition deficit, social stress, 5-HT Neuropharmacology, 2017, Volume: 112, Issue:Pt A Topics: Acetamides; Aminopyridines; Anhedonia; Animals; Dendrites; Indoles; Mice; Mice, Knockout; Olfactory Bulb; Protein Subunits; Receptor, Serotonin, 5-HT2C; Receptors, N-Methyl-D-Aspartate; Recognition, Psychology; Serotonin 5-HT2 Receptor Antagonists; Social Behavior; Social Isolation; Stress, Psychological	2017

chemdatabank.com